Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 20/20 | 0.58 |
| ▸ | CRBN | Q96SW2 | 20/20 | 0.58 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21997352 | 0.94 | CRBN (0.56) | DDB1CRBNIKZF3 | |
| SCHEMBL30169304 | 0.93 | CRBN (0.55) | DDB1CRBNIKZF3 | |
| SCHEMBL22526735 | 0.93 | CRBN (0.55) | DDB1CRBNIKZF3 | |
| SCHEMBL22526201 | 0.92 | CRBN (0.54) | DDB1CRBNIKZF3 | |
| SCHEMBL30990646 | 0.92 | CRBN (0.54) | DDB1CRBNIKZF3 | |
| SCHEMBL25123384 | 0.92 | CRBN (0.54) | DDB1CRBNIKZF3 | |
| SCHEMBL22526772 | 0.92 | CRBN (0.54) | DDB1CRBNIKZF3 | |
| SCHEMBL22526770 | 0.92 | CRBN (0.54) | DDB1CRBNIKZF3 | |
| SCHEMBL30990811 | 0.92 | CRBN (0.54) | DDB1CRBNIKZF3 | |
| SCHEMBL30169198 | 0.92 | CRBN (0.54) | DDB1CRBNIKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260070917-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | DIFFERENTIATED THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4665332-A2 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | Differentiated Therapeutics Inc (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250302815-A1 | PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS | CALICO LIFE SCIENCES LLC | 2025-10-02 | — | — | US | disclosed |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12258341-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| WO-2024173412-A2 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | DIFFERENTIATED THERAPEUTICS, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| EP-4384512-A1 | PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS | Calico Life Sciences LLC (US) | 2024-06-19 | — | — | EP | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20220324854-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| EP-3886904-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| CN-113423427-A | IRAK degrading agents and uses thereof | 凯麦拉医疗公司 | 2021-09-21 | — | — | CN | disclosed |
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| WO-2020113233-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258341-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | DDB1 1267/4885CRBN 187/4885IKZF3 135/4885 |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | DDB1 1267/4885CRBN 187/4885IKZF3 135/4885 |
| US-20250302815-A1 | PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS | PTPN1, PTPN2, PTPN18 | DDB1 1385/4885CRBN 230/4885IKZF3 1804/4885 |
| US-11117889-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | DDB1 1267/4885CRBN 187/4885IKZF3 135/4885 |
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | DDB1 1267/4885CRBN 187/4885IKZF3 135/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | DDB1 1267/4885CRBN 187/4885IKZF3 135/4885 |
| US-20220324854-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | DDB1 1267/4885CRBN 187/4885IKZF3 135/4885 |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | DDB1 1267/4885CRBN 187/4885IKZF3 135/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | DDB1 1267/4885CRBN 187/4885IKZF3 135/4885 |
| US-20260070917-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | CDK2, CCNK, CCNC | DDB1 270/4885CRBN 277/4885IKZF3 2841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.